Drug
Eteplirsen
Eteplirsen: highest development phase Phase 3, developed by Sarepta Therapeutics. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sarepta Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| eteplirsen NCT02255552 | Phase 3 | Duchenne Muscular Dystrophy (DMD) |
| Eteplirsen NCT03992430 | Phase 3 | Muscular Dystrophy, Duchenne |
| eteplirsen NCT02420379 | Phase 2 | Duchenne Muscular Dystrophy (DMD) |
| Eteplirsen NCT03218995 | Phase 2 | Duchenne Muscular Dystrophy |
| Eteplirsen NCT02286947 | Phase 2 | Muscular Dystrophy, Duchenne |
Latest
Follow Eteplirsen on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.